However, whether the activation of the pSTAT3/CEBPD/MCL1 axis plays a common and vital role in the development of leptin-associated cancers as well as the idea of combined targeting of STAT3 and MCL1 to block mitochondrial fusion and stemness activity for GBC therapy deserve to be investigated in the future. The gene discussed is CEBPD; the disease is cancer.